ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-5715721,916
Cost of Revenue-17--
Gross Profit-5545721,916
Operating Expenses
Research Development-27,16831,23035,895
Selling General and Administrative109,13661,34530,32623,458
Non Recurring----
Total Operating Expenses149,06988,53061,55659,353
Operating Income or Loss-115,023-87,959-60,984-57,437
Income from Continuing Operations
Total Other Income/Expenses Net-15,976-3,261811363
Earnings Before Interest and Taxes-115,023-87,959-60,984-57,437
Interest Expense--4,645-4,645-4,645
Income Before Tax--91,220-60,173-57,074
Income Tax Expense--1,730-115-5,272
Minority Interest----
Net Income From Continuing Ops--89,490-60,058-51,802
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income--89,490-60,058-51,802
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares--89,490-60,058-51,802